Orange Book product · Generic (ANDA)
CYTARABINE
CYTARABINE
At a glance
Feb 28, 2022
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 28, 2022
4 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
CYTARABINE
Strength
20MG/ML
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 208485
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CYTARABINE
- 1999DEPOCYTBrand (NDA)
NDA 021041 · PACIRA PHARMS INC
- 1987CYTARABINEBrand (NDA)
NDA 016793 · TEVA PARENTERAL
- 2020CYTARABINEGeneric (ANDA)
ANDA 206189 · MEITHEAL
- 2019CYTARABINEGeneric (ANDA)
ANDA 211938 · GLAND
- 2019CYTARABINEGeneric (ANDA)
ANDA 211937 · GLAND
- 2018CYTARABINEGeneric (ANDA)
ANDA 205696 · MEITHEAL
- 2017CYTARABINEGeneric (ANDA)
ANDA 206190 · MEITHEAL
- 2012CYTARABINEGeneric (ANDA)
ANDA 201784 · RISING
- 2011CYTARABINEGeneric (ANDA)
ANDA 200916 · PHARMOBEDIENT
- 2011CYTARABINEGeneric (ANDA)
ANDA 200914 · RISING
- 2011CYTARABINEGeneric (ANDA)
ANDA 200915 · RISING
- 2004CYTARABINEGeneric (ANDA)
ANDA 076512 · FRESENIUS KABI USA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
